These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 6965669)

  • 1. Adjuvant immunotherapy with a S. pyogenes preparation (OK432) in urogenital cancer patients.
    Nakagami Y; Chin H; Tannowa K; Matsumoto K; Kawai H
    Invest Urol; 1980 Mar; 17(5):386-9. PubMed ID: 6965669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [An experience of OK-432 intradermal administration in superficial bladder tumors].
    Tsujihashi H; Akiyama T; Kurita T; Iguchi M; Uejima S; Kataoka K; Minakata S; Kitagawa M; Sangen H
    Hinyokika Kiyo; 1988 Dec; 34(12):2111-4. PubMed ID: 3239522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histological changes caused by intralesional injection of a streptococcal preparation into bladder cancer.
    Fujita K
    Cancer Detect Prev; 1988; 11(3-6):397-403. PubMed ID: 3292046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Studies of immunotherapy of malignant urogenital tumors: 2nd report. Changes in the K-cell population of the peripheral blood in patients with malignant tumors and the significance of antibody dependent cell-mediated cytotoxicity (ADCC) in OK-432 immunotherapy].
    Fujioka T; Tanji S; Koike H; Suzuki K; Aoki H; Banya Y; Kubo T; Ohhori T
    Nihon Hinyokika Gakkai Zasshi; 1987 Jan; 78(1):29-38. PubMed ID: 3599595
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of biological response modifier on thoracic duct lymphocytes in recurrent gastric cancer. Evaluation of OK-432, a hemolytic streptococcus preparation.
    Hanaue H; Kim DY; Kubota M; Kurosawa T; Shikata J; Kondoh Y; Ogoshi K; Makuuchi H; Nakasaki H; Mitomi T
    Tokai J Exp Clin Med; 1987 May; 12(2):97-102. PubMed ID: 3502432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunotherapy of terminal-stage malignant tumors with the immunopotentiator OK-432--a comparison between SU-PS test-responder and -nonresponder patients].
    Yagi Y; Yagi S; Ichiki H
    Gan No Rinsho; 1987 Jun; 33(7):815-21. PubMed ID: 3302349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blastogenic responses of human lymphocytes to a streptococcal preparation OK-432 and its fractions.
    Tanaka T; Kaneko Y; Haba F; Katsuta S; Tsutsui K; Tamaki S; Chen DR; Suzuki S; Ueda R; Yamamoto A
    J Clin Lab Immunol; 1989 Feb; 28(2):91-6. PubMed ID: 2787407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profile of T-cell receptor V beta gene usage of cytotoxic T cells induced by intrapleural administration of a streptococcal preparation, OK432, in malignant effusions.
    Miyahara E; Yamaguchi Y; Hihara J; Noma K; Toge T
    J Exp Ther Oncol; 1996 Jul; 1(4):242-50. PubMed ID: 9414411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Non-specific immunotherapy with OK-432, streptococcus pyogenes preparation, for inoperable cancer patients of the digestive tract].
    Hanaue H; Nomoto S; Yoshizaki S; Kitano Y; Miyakawa S; Horie F; Kurosawa T; Nemoto A; Yasuda H; Takada T
    Nihon Gan Chiryo Gakkai Shi; 1984 Jul; 19(6):1307-14. PubMed ID: 6512346
    [No Abstract]   [Full Text] [Related]  

  • 10. [Intratumoral administration of OK432 in rats with liver tumor].
    Ishimaru M
    Nihon Geka Gakkai Zasshi; 1988 Jun; 89(6):880-8. PubMed ID: 2972906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of streptococcal preparation (OK-432) local injection in patients with urinary bladder carcinoma.
    Nishio S; Izeki T; Wada S; Morikawa Y; Yasumoto R; Maekawa M
    Osaka City Med J; 1980; 26(1):47-59. PubMed ID: 7267092
    [No Abstract]   [Full Text] [Related]  

  • 12. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
    Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M
    Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between lymphocyte responsiveness to mitogens and results of chemo-immunotherapy in patients with advanced cancer.
    Toge T; Yamada Y; Ikeda H; Niimoto M; Hattori T
    Gan; 1979 Oct; 70(5):699-703. PubMed ID: 520761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Changes in ASP (antigroup-A streptococcal C polysaccharide antibody) and cardiac and renal effects in cases of urogenital cancers during OK-432 immunotherapy, streptococcus preparation].
    Tanji S; Koike H; Kumagai K; Fujioka T; Kubo T; Ohhori T; Yoshida I
    Nihon Hinyokika Gakkai Zasshi; 1988 Jan; 79(1):49-57. PubMed ID: 3398379
    [No Abstract]   [Full Text] [Related]  

  • 15. [The Su-polysaccharide skin test in lung cancer].
    Harada J; Horiguchi T; Oki K; Miyamoto H; Osada T
    Gan To Kagaku Ryoho; 1987 Sep; 14(9):2697-702. PubMed ID: 3307634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Administration of hemolytic streptococcus preparation OK-432 on recurrent gastric carcinoma].
    Hanaue H; Kurosawa T; Kitano Y; Miyagawa S; Nemoto A; Yamato H; Asagoe T; Shikata J
    Nihon Gan Chiryo Gakkai Shi; 1987 Aug; 22(7):1367-72. PubMed ID: 3501455
    [No Abstract]   [Full Text] [Related]  

  • 17. A newer hyperthermic therapy with a bacterial immunopotentiator (OK432) for chemotherapy-resistant ovarian cancer.
    Nishida T; Oda T; Sugiyama T; Yakushiji M; Kato T
    Nihon Sanka Fujinka Gakkai Zasshi; 1984 Jan; 36(1):142-6. PubMed ID: 6199441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [An experimental study on the induction of anti-tumor immunological activity after cryosurgery for liver carcinoma, and the effect of concomitant immunotherapy with OK432].
    Hanawa S
    Nihon Geka Gakkai Zasshi; 1993 Jan; 94(1):57-65. PubMed ID: 8437553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [OK432 chemical pleurodesis as a standard therapy of spontaneous pneumothorax].
    Ishihara K; Hasegawa T; Okazaki M; Katakami N; Sakamoto H; Lee E; Iwasaki H; Umeda B; Nakai H
    Nihon Kyobu Shikkan Gakkai Zasshi; 1988 Jan; 26(1):10-5. PubMed ID: 3373914
    [No Abstract]   [Full Text] [Related]  

  • 20. Combined immunotherapy with intracavital injection of activated lymphocytes, monocyte-derived dendritic cells and low-dose OK-432 in patients with malignant effusion.
    Morisaki T; Matsumoto K; Kuroki H; Kubo M; Baba E; Onishi H; Tasaki A; Nakamura M; Inaba S; Katano M
    Anticancer Res; 2003; 23(6a):4459-65. PubMed ID: 14666734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.